TargetMol

Ivermectin

Product Code:
 
TAR-T1131
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
 

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T1131-200mg200mg£96.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1131-500mg500mg£113.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1131-1mL1 mL * 10 mM (in DMSO)£116.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1131-1g1g£128.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Ivermectin is a glutamate-gated chloride channel (GluCls) activator, with antiparasitic activity.
CAS:
70288-86-7
Formula:
C48H74O14
Molecular Weight:
875.106
Pathway:
Microbiology/Virology; Membrane transporter/Ion channel; Autophagy; Neuroscience; Proteases/Proteasome
Purity:
0.9774
SMILES:
CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](CC=C(C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)C=CC=C3/CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2
Target:
Mitophagy; GluCls; P2X Receptor; SARS-CoV; HIV Protease; Antibiotic; Parasite; Autophagy; HSV

References

1. Wagstaff KM, et al. Biochem J, 2012, 443(3), 851-856. 2. Reiter RJ, et al. Prog Neurobiol, 1998, 56(3), 359-384. 3. Moreno Y, et al. Proc Natl Acad Sci U S A, 2010, 107(46), 20120-20125. 4. Yardley MM, et al. Neuropharmacology, 2012, 63(2), 190-201. 5. Zhang X, et al. Inflamm Res, 2008, 57(11), 524-529.